Pulmonary Sarcoidosis Market Forecast Signals Robust Industry Growth Through 2032 - DelveInsight

The Pulmonary Sarcoidosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Sarcoidosis pipeline products will significantly revolutionize the Pulmonary Sarcoidosis market dynamics.

DelveInsight's "Pulmonary Sarcoidosis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Pulmonary Sarcoidosis, historical and forecasted epidemiology as well as the Pulmonary Sarcoidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Pulmonary Sarcoidosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Pulmonary Sarcoidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pulmonary Sarcoidosis Market Insights
https://www.delveinsight.com/sample-request/pulmonary-sarcoidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Pulmonary Sarcoidosis Market Report:
• The Pulmonary Sarcoidosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In May 2025, aTyr Pharma, Inc. (Nasdaq: ATYR), referred to as "aTyr," is developing Efzofitimod, a novel biologic immunomodulator, for the treatment of interstitial lung disease (ILD)-a group of immune-related conditions that lead to lung inflammation and scarring (fibrosis). Derived from tRNA synthetase, Efzofitimod works by targeting activated myeloid cells via neuropilin-2, aiming to reduce inflammation without suppressing the immune system and potentially slowing fibrosis progression. The company is currently evaluating the drug in the Phase 3 EFZO-FITTM trial for pulmonary sarcoidosis, a common type of ILD, and in the Phase 2 EFZO-CONNECTTM trial for systemic sclerosis-related ILD (scleroderma).
• In March 2025, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical-stage biotech company developing first-in-class therapies from its proprietary tRNA synthetase platform, announced the results of a fourth planned interim safety review for its ongoing Phase 3 EFZO-FITTM trial. Conducted by an independent data and safety monitoring board (DSMB), the analysis supported the continuation of the study without any changes, affirming the safety profile of the company's lead candidate, efzofitimod, in patients with pulmonary sarcoidosis.
• In a study by Denning DW et al. (2013), published in European Respiratory Journal, out of total patients of Sarcoidosis, approximately 90% of patients have pulmonary sarcoidosis which is characterized by the accumulation of granulomas, or small clusters of immune cells, in the lungs, potentially leading to enlarged lymph nodes, pulmonary hypertension, and fibrosis
• Key Pulmonary Sarcoidosis Companies: aTyr Pharma, Inc., Kinevant Sciences GmbH, aTyr Pharma, Inc., Novartis Pharmaceuticals, Mallinckrodt, Kinevant Sciences GmbH, Actelion, and others
• Key Pulmonary Sarcoidosis Therapies: ATYR1923, Namilumab, CMK389, Efzofitimod, CMK389, ACZ885, Acthar Gel, Namilumab, Selexipag, Bosentan, and others
• The Pulmonary Sarcoidosis epidemiology based on gender analyzed that Pulmonary Sarcoidosis is more common in women than in men

Get a Free sample for the Pulmonary Sarcoidosis Market Report
https://www.delveinsight.com/report-store/pulmonary-sarcoidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pulmonary Sarcoidosis Overview
Pulmonary Sarcoidosis is a type of sarcoidosis that primarily affects the lungs. It is an inflammatory disease where clusters of immune cells called granulomas form in the lung tissue, leading to inflammation and scarring. The exact cause is unknown, but it may be linked to an abnormal immune response to environmental or infectious agents. Common symptoms include persistent dry cough, shortness of breath, chest pain, and fatigue. While some cases resolve on their own, others may require treatment with corticosteroids or immunosuppressive drugs. In severe cases, pulmonary sarcoidosis can lead to lung fibrosis and reduced lung function.

Pulmonary Sarcoidosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Pulmonary Sarcoidosis Epidemiology Segmentation:
The Pulmonary Sarcoidosis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Pulmonary Sarcoidosis
• Prevalent Cases of Pulmonary Sarcoidosis by severity
• Gender-specific Prevalence of Pulmonary Sarcoidosis
• Diagnosed Cases of Episodic and Chronic Pulmonary Sarcoidosis

Download the report to understand which factors are driving Pulmonary Sarcoidosis epidemiology trends @ Pulmonary Sarcoidosis Epidemiological Insights
https://www.delveinsight.com/sample-request/pulmonary-sarcoidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pulmonary Sarcoidosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Sarcoidosis market or expected to get launched during the study period. The analysis covers Pulmonary Sarcoidosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pulmonary Sarcoidosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Pulmonary Sarcoidosis Therapies and Key Companies
• ATYR1923: aTyr Pharma, Inc.
• Namilumab: Kinevant Sciences GmbH
• CMK389: Novartis
• Efzofitimod: aTyr Pharma, Inc.
• CMK389: Novartis Pharmaceuticals
• ACZ885: Novartis
• Acthar Gel: Mallinckrodt
• Namilumab: Kinevant Sciences GmbH
• Selexipag: Actelion
• Bosentan: Actelion

To know more about Pulmonary Sarcoidosis treatment, visit @ Pulmonary Sarcoidosis Medications
https://www.delveinsight.com/sample-request/pulmonary-sarcoidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pulmonary Sarcoidosis Market Drivers
• Increasing prevalence of chronic inflammatory and granulomatous lung disorders is driving demand for effective pulmonary sarcoidosis therapies.
• Rising awareness and improved diagnostic technologies such as high-resolution imaging and biomarker-based testing are supporting earlier disease detection.
• Growing research activities focused on immune-mediated respiratory diseases are expanding understanding of pulmonary sarcoidosis pathogenesis and treatment options.
• Advancements in biologics, immunomodulators, and targeted anti-inflammatory therapies are improving disease management outcomes.
• Increasing healthcare expenditure and better access to specialized pulmonary care centers are supporting treatment adoption.

Pulmonary Sarcoidosis Market Barriers
• Limited understanding of the exact disease etiology and heterogeneous clinical presentation can complicate diagnosis and treatment decisions.
• Lack of approved disease-specific therapies in several regions remains a major unmet medical need.
• Long-term dependence on corticosteroids may lead to significant side effects and reduced patient compliance.
• Delayed diagnosis due to symptom overlap with other respiratory diseases such as tuberculosis and pulmonary fibrosis may hinder early intervention.
• Limited patient population and variable disease progression can restrict large-scale clinical trial development.

Scope of the Pulmonary Sarcoidosis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Pulmonary Sarcoidosis Companies: aTyr Pharma, Inc., Kinevant Sciences GmbH, Novartis, aTyr Pharma, Inc., Novartis Pharmaceuticals, Mallinckrodt, Kinevant Sciences GmbH, Actelion, and others
• Key Pulmonary Sarcoidosis Therapies: ATYR1923, Namilumab, CMK389, Efzofitimod, CMK389, ACZ885, Acthar Gel, Namilumab, Selexipag, Bosentan, and others
• Pulmonary Sarcoidosis Therapeutic Assessment: Pulmonary Sarcoidosis current marketed and Pulmonary Sarcoidosis emerging therapies
• Pulmonary Sarcoidosis Market Dynamics: Pulmonary Sarcoidosis market drivers and Pulmonary Sarcoidosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Pulmonary Sarcoidosis Unmet Needs, KOL's views, Analyst's views, Pulmonary Sarcoidosis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.